Finasteride

The new program provides access to virtual consultations and pharmacy-filled prescriptions for oral minoxidil and finasteride under clinician supervision. DENVER, May 21, 2025 /PRNewswire/ -- Eden, the leading health platform connecting individuals with licensed providers and pharmacies focused on metabolic health, today announced the launch of its clinician-guided Hair Wellness Program. The program enables adults across the U.S. to explore prescription-based options such as oral minoxidil and finasteride following a virtual consultation with a licensed provider. If a prescription is issued, it is filled by a state-licensed compounding pharmacy and shipped directly to the member's door. Other oral therapies (such as minoxidil and finasteride or spironolactone) are expected to become available later this year through Eden's provider and pharmacy network. Eden's program is designed to offer individuals convenient access to medical evaluations and pharmacy-prepared treatments under the supervision of licensed professionals. The process requires telehealth visits and includes follow-up support to help patients stay informed and aligned with their provider's care plan. "Hair-related concerns are often part of broader conversations around aging and wellness," said Adam McBride, CEO of Eden. "We created this program to give adults the ability to speak with a provider from home and access treatments that are typically hard to get outside of specialist clinics." Key Program Components: Telehealth Intake – Patients complete a secure health questionnaire and meet virtually with a licensed provider to assess eligibility for treatment. Prescription Fulfillment – If appropriate, providers may prescribe oral minoxidil or finasteride. These are compounded medications prepared by state licensed pharmacies and shipped directly to the patient. Ongoing Support – Eden's care coordination team offers follow-up check-ins at key milestones to help patients stay on track and informed throughout their care journey. Oral minoxidil is a vasodilator that has been studied for off-label use in addressing certain hair-related concerns. Oral finasteride is FDA-approved for male pattern hair loss and may also be prescribed off-label in other contexts, based on a provider's clinical judgment. Compounded medications are customized for individual patients by licensed pharmacies and are not FDA-approved. They are prepared in accordance with provider orders to meet unique medical needs. "This is about giving patients access to licensed care, clear guidance, and personalized formulations," said Dr. Rebecca Emch, PharmD, VP of Pharmacy and Medical Operations at Eden. "Our platform makes it easier for people to receive provider input and trusted treatment options." "People want solutions that are professional, personalized, and backed by expertise, not more guesswork from store shelves or unregulated practitioners," said Josh Khan, President and Co-Founder at Eden. "We're excited to expand access to care that fits into real life and supports how people want to look and feel." Pricing and Availability The Hair Wellness Program is available in all 50 states. Plans start at $29/month. Medication is included only if prescribed and clinically appropriate. About Eden Eden is a health company that connects individuals with licensed doctors, compounding pharmacies, and nutrition solutions designed to support metabolic health. Through a seamless online experience, Eden helps patients explore personalized treatment options, offering a convenient approach to overall wellness support. Certain therapies described may be prescribed off-label, based on clinical discretion. These statements have not been evaluated by the Food and Drug Administration. Compounded medications accessed via Eden's network are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. SOURCE Eden WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Bengaluru: The European drugs regulator said on Thursday its safety panel has confirmed suicidal thoughts as a side effect of anti-hair-loss drug finasteride and its generic versions, following an EU-wide review of available data. Most cases of suicidal thoughts were reported in people using 1 milligram (mg) finasteride tablets, which are used to treat androgenetic alopecia - a condition of hair loss brought on by male hormones. The frequency of the side effect could not be determined from available data, the European Medicines Agency said. The health agency said in October last year it was reviewing anti-hair-loss drugs finasteride and dutasteride over the risk of suicidal thoughts. The drugs have a known risk of psychiatric side effects. Finasteride, which Organon sells under brand name Propecia, already comes with warnings about the risk of suicidal thoughts. The EMA, however, added that it was not possible to establish a link between suicidal ideation and dutasteride tablets based on the reviewed data. British drugmaker GSK sells dutasteride under brand name Avodart. Generic versions of finasteride and dutasteride are available in the market. Organon and GSK did not immediately respond to Reuters' requests for comment on EMA's statement. Finasteride and dutasteride are also used to treat a prostate condition called benign prostatic hyperplasia. The panel agreed that suicidal thoughts should be included as a side effect for finasteride tablets, but said the benefits of finasteride and dutasteride medicines continue to outweigh their risks for all approved uses. A patient card will be included in the packages of 1 mg finasteride tablets to remind patients of these risks and to advise them about the appropriate course of action, the health regulator said. Information about the mood changes seen with finasteride will also be added to dutasteride's product information as a precaution. (Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli and Shailesh Kuber)